Skip to main content
. 2009 Jun 9;84(1):111–118. doi: 10.1093/cvr/cvp190

Figure 3.

Figure 3

Perturbations in levels of cardiac SGLT1 mRNA expression as measured by QPCR in diseased human hearts. Significant increases in SGLT1 expression were observed in subjects with end-stage cardiomyopathy secondary to (A) long-standing type 2 diabetes and (B) coronary artery disease, relative to age- and sex-matched control subjects. (C) No change in SGLT1 expression was observed in idiopathic dilated cardiomyopathy. (D) In failing hearts, implantation of left ventricular assist devices (LVAD) resulted in an increase in SGLT1 expression, which correlated with improved contractile function. Paired samples from the same subjects were used. n = 5–6 per group. Data are expressed as mean ± SE. *P < 0.05; †P < 0.01; ‡P < 0.001 relative to control or baseline.